Healthcare in Crisis: Cera Secures $150 Million to Scale AI-Driven Home Healthcare Platform
Background
Around the world, public healthcare systems have struggled to reset post-pandemic, and in particular, the increasingly aged populations in Western countries are putting pressure on services, not least in the UK where ‘NHS in crisis’ is a regular headline in the media. As a result, private companies, many powered with technology, see a gap in the market.
Funding and Partnership
Cera, a proprietary software platform and in-home healthcare provider in the UK, has raised a $150 million in a mixture of debt and equity. The round was led by funds affiliated with BDT & MSD Partners and Schroders Capital to scale the company’s platform.
Company Overview
According to CrunchBase, Cera has 14 investors, including Earlymarket, Guinness Ventures, DigitalHealth, London Accelerator, and long-time U.K. investor Robin Klein. The company’s AI-driven platform uses proprietary modeling based on its own data, with aspects of Google’s Gemini AI platform and Microsoft’s ChatGPT.
Business Milestones
In 2022, Cera raised $320 million (£260 million) in an equity and debt financing round, split roughly 50/50. The company has raised more than $407 million to date in a mix of equity and debt.
Competitors
Competitors in the U.K. include Home Instead and Bluebird Care, which use non-proprietary apps to direct their staff. In the US, the closest comparisons to Cera include Signify Health and CVS Health, both of which were acquired by Nasdaq-listed CVS Health. Another is Honor, which has raised $625 million to date.
AI-Driven Home Healthcare
Cera’s AI-driven home healthcare platform uses its app to plan carers’ work and log patient symptoms. The company claims this has resulted in hospitalization reductions of up to 70%, a 20% reduction in patient falls, and hospital discharges that are up to five times faster.
Conclusion
Cera is well-positioned to further scale its business, with strong growth and a demonstrated ability to leverage technology to deliver exceptional care. With its AI-driven platform and comprehensive range of services, the company is poised to make a significant impact in the healthcare industry.
FAQs
Q: What is Cera’s business model?
A: Cera is a proprietary software platform and in-home healthcare provider in the UK, using AI-driven technology to deliver exceptional care.
Q: Who are Cera’s investors?
A: Cera has 14 investors, including Earlymarket, Guinness Ventures, DigitalHealth, London Accelerator, and long-time U.K. investor Robin Klein.
Q: What are Cera’s competitors?
A: Competitors in the U.K. include Home Instead and Bluebird Care, while in the US, the closest comparisons to Cera include Signify Health and CVS Health.
Q: What are the benefits of Cera’s AI-driven platform?
A: Cera’s AI-driven platform has resulted in hospitalization reductions of up to 70%, a 20% reduction in patient falls, and hospital discharges that are up to five times faster.
